Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.

ABSTRACT:

Background

Several monoclonal antibodies (mAbs) recognising Lewis(y), such as BR96, have reached the clinic but have failed to show good anti-tumour responses with an acceptable level of toxicity. No Lewis(b) mAbs have been trialled in patients. In this study we compare the specificity of three mAbs; BR96 (Lewis(y)), 2-25 LE (Lewis(b)) and 692/29 that recognises a unique facet of both Lewis(y) and Lewis(b). We then assessed the in vivo therapeutic effect of 692/29 using xenograft models.

Methodology/principal findings

Using a glycan array, each mAb was shown to display a different binding pattern with only 692/29 binding to both Lewis(y) and Lewis(b). 692/29 was able to kill tumour cells over-expressing Lewis(y/b) directly, as well as by antibody and complement mediated cyto

SUBMITTER: Noble P 

PROVIDER: S-EPMC3568143 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature